My take on today3 Jan 2018 20:07
I am not sure what to make of todays conference call but listening to the questions & answers from the 5 institutions I learnt as follows:
1) The answer given to J.P.Morgan as to 'cash back' from the deal suggests that Summit are yet to decide which aspects of Discuva's work they will go for so not yet able to say how things will work out plan wise.
2)In another answer from another institution on staffing etc in relation to the additional costs it was said there would be 10 staff being kept & the floor space was 7,000 to 8,000 square feet.By using the phrase staff being kept in the answer suggests that not all staff have stayed with Discuva.
3)In another answer from another institution question Roche deal was not the driver for the purchase & any income from it in my words would be a bonus.
In addition that because Roche was now going in house there was less income for Discuva who needed further funding for further development.It seems to me that the baton has been passed onto Summit avoiding need for further external funding.
In addition to other questions Glyn mentioned that the Company could be split, once the DMD results are known, into a DMD Company & a C-Diff/Discuva Company which I think would facilitate Buy outs to create investor appreciation.
In summary it seems to me that the cash benefits from the Discuva deal will not be known until Summit have decided the direction it will take Discuva's work.Having followed Discuva before the RNS, as I have said before, I have regarded it as being at the cutting edge of technology for the fight against anti-biotic resistance & now combined with Summit could make Summit a 'world class' leader in this field but true share holder appreciation would be a few years further down the line.
Sign In
Follow the stocks
